Stay updated on Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.

Latest updates to the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page
- Check3 days agoChange DetectedThe footer revision identifier changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe site footer’s revision label updates from v3.7.2 to v3.8.0, while the clinical trial record and its version history remain unchanged.SummaryDifference0.0%

- Check31 days agoChange DetectedA site-wide notice was added about NIH’s transition from “Artificial Intelligence” to “Super Intelligence,” and the site revision number changed from v3.7.1 to v3.7.2.SummaryDifference0.3%

- Check45 days agoChange DetectedThe footer’s ClinicalTrials.gov site revision number changed from v3.7.0 to v3.7.1.SummaryDifference0.0%

- Check66 days agoChange DetectedThe history now shows a new revision entry (v3.7.0) representing the latest update to the study record. The previous revision (v3.6.6) is no longer listed in the current version history.SummaryDifference0.0%

- Check80 days agoChange DetectedA new revision entry 'Revision: v3.6.6' was added to the history, signaling an update to the record; the previous 'Revision: v3.6.5' entry was noted as removed in the change set.SummaryDifference0.0%

Stay in the know with updates to Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.